News

Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...
Novo Nordisk CEO's ouster signals stiff competition in the obesity market, getting dominated by Eli Lilly, with Roche, ...
As Denmark's Novo Nordisk shops for its next CEO to replace Lars Fruergaard Jorgensen, it should look across the Atlantic for a leader deeply entrenched in the United States, by far its largest market ...
Ozempic-maker Novo Nordisk on Friday ousted its CEO Lars Fruergaard Jorgensen over concerns the company is losing its ...
COPENHAGEN (Reuters) - Wegovy-maker Novo Nordisk (NYSE: NVO) ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the ...
(Reuters) -As Denmark's Novo Nordisk shops for its next CEO to replace Lars Fruergaard Jorgensen, it should look across the ...
Lars Fruergaard Jorgensen, who has headed the pharmaceutical company for eight years, will step down after a period to ...
Much has been learned about GLP-1s over many years, but little is understood about why the degree of response to them varies ...